Pharma Capital

M Pharmaceutical becomes Callitas Therapeutics to better align with its expertise

"As a company with its roots in female health and wellness, we are committed to delivering breakthrough products...," the firm said
M Pharmaceutical Inc becomes Callitas Therapeutics Inc to better align with its expertise
A Calla lily

M Pharmaceutical Inc (CNSX:MQ) told investors it had changed its name to Callitas Therapeutics Inc to  "better align with its expertise in the health care field".

Formed in early 2015, Callitas is a clinical-stage company developing technologies to treat obesity, for weight management, and for female health and wellbeing.

"As a company with its roots in female health and wellness, we are committed to delivering breakthrough products and services that truly improve daily living," said Gary Thompson, its president and chief executive.

"Aligning our logo with the beautiful and strong Calla Lily seems most appropriate in light of our mission."

The group has recently bought C-103, a reformulation of Orlistat, and assets from 40J's LLC.

M Pharma is also scheduled to launch its Food and Drug Administration-cleared fertility product branded as ToConceive some time in September this year.

The name of the parent company remains as it is for now, the company said.

A new corporate website is available on-line.

Giles_55af4ddca6481.jpg
Why Invest In Callitas Therapeutics Inc? Read More Here

Register here to be notified of future MQ Company articles
View full MQ profile

Callitas Therapeutics Inc Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.